Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer

US Patent 11547705 · Granted Jan 10, 2023

Estimated economic value: $1,732,471,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Dosage and administration of anti-C5 antibodies for treatment of atypical hemoly2025
Tumor-treating pharmaceutical composition2025
Nanoparticle vaccine adjuvant and methods of use thereof2025
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor 2024
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor 2024
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor 2024
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor 2024
Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating can2024
Nanoparticle vaccine adjuvant and methods of use thereof2023
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhib2022
Methods for treating hypophosphatasia (HPP) in adults and adolescents2022
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating can2020